Predictors of Renal Structural Alterations in Hypothyroid Patients The Role of Physical Inactivity and Clinical Parameters
Keywords:
hypothyroidism, renal structural alterations, renal ultrasonography, clinical predictors, renal morphometryAbstract
Background: Hypothyroidism may influence renal physiology through alterations in cardiovascular performance, renal hemodynamics, and glomerular filtration. Identifying clinical characteristics potentially associated with renal structural alterations may contribute to a more comprehensive understanding of kidney involvement in patients with hypothyroidism.
To investigate potential clinical predictors of renal structural alterations in patients with hypothyroidism, with particular attention to physical inactivity and available clinical parameters.
The available information establishes the study population and the renal assessment methods. However, patient-level data and statistical estimates required to identify predictors of renal structural alterations have not yet been provided. Therefore, no predictor effects, associations, or significance levels are reported in this draft.
The study provides a basis for examining potential relationships between clinical characteristics and renal morphology in patients with hypothyroidism. Identification of independent predictors requires verified clinical and ultrasound data, a clearly defined physical-activity measure, and an appropriate multivariable statistical analysis.
References
[1] P. Iglesias, M. A. Bajo, R. Selgas, and J. J. Díez, “Thyroid dysfunction and kidney disease: An update,” Reviews in Endocrine and Metabolic Disorders, vol. 18, no. 1, pp. 131–144, 2017, doi: 10.1007/s11154-016-9395-7.
[2] A. I. Katz, D. S. Emmanouel, and M. D. Lindheimer, “Thyroid hormone and the kidney,” Nephron, vol. 15, nos. 3–5, pp. 223–249, 1975, doi: 10.1159/000180514.
[3] C. M. Rhee, “The interaction between thyroid and kidney disease: An overview of the evidence,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 23, no. 5, pp. 407–415, 2016, doi: 10.1097/MED.0000000000000275.
[4] X. Wang, X. Shang, Y. Li, C. Lu, Y. Shao, D. Yang, W. Teng, and X. Shi, “Association between hypothyroidism, levothyroxine replacement and kidney function outcomes: A systematic review and meta-analysis,” Frontiers in Endocrinology, vol. 17, Art. no. 1841255, 2026, doi: 10.3389/fendo.2026.1841255.
[5] C. M. Rhee and Y. Narasaki, “Hormones and nephrons: Disentangling the thyroid-kidney connection,” Clinical Journal of the American Society of Nephrology, vol. 20, no. 7, pp. 905–908, 2025, doi: 10.2215/CJN.0000000761.
[6] P. Dousdampanis, K. Trigka, G. A. Vagenakis, and C. Fourtounas, “The thyroid and the kidney: A complex interplay in health and disease,” International Journal of Artificial Organs, vol. 37, no. 1, pp. 1–12, 2014, doi: 10.5301/ijao.5000300.
[7] C. Ellervik, S. Mora, P. M. Ridker, D. I. Chasman, et al., “Hypothyroidism and kidney function: A Mendelian randomization study,” Thyroid, vol. 30, no. 3, pp. 365–379, 2020, doi: 10.1089/thy.2019.0167.
[8] Kidney Disease: Improving Global Outcomes KDIGO CKD Work Group, “KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease,” Kidney International, vol. 105, no. 4S, pp. S117–S314, 2024, doi: 10.1016/j.kint.2023.10.018.
[9] B. B. Rabiev, “Women’s migration and childhood illness social determinants of health,” Journal of Family Medicine and Health Care, vol. 12, no. 2, pp. 27–32, 2026, doi: 10.11648/j.jfmhc.20261202.11.
[10] C. P. Kovesdy, “Epidemiology of chronic kidney disease: An update 2022,” Kidney International Supplements, vol. 12, no. 1, pp. 7–11, 2022, doi: 10.1016/j.kisu.2021.11.003.
[11] L. H. Mariani and J. S. Berns, “The renal manifestations of thyroid disease,” Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 22–26, 2012, doi: 10.1681/ASN.2010070766.
[12] U. T. Schultheiss, N. Daya, M. E. Grams, J. Seufert, M. Steffes, J. Coresh, E. Selvin, and A. Köttgen, “Thyroid function, reduced kidney function and incident chronic kidney disease in a community-based population: The Atherosclerosis Risk in Communities study,” Nephrology Dialysis Transplantation, vol. 32, no. 11, pp. 1874–1881, 2017, doi: 10.1093/ndt/gfw301.
[13] I. Al Fahdi, I. Al Salmi, F. Al Rahbi, F. Shaheen, and S. Hannawi, “Thyroid dysfunction and kidney dysfunction,” Oman Medical Journal, vol. 37, no. 3, Art. no. e377, 2022, doi: 10.5001/omj.2022.55.
[14] A. Levin, S. B. Ahmed, J. J. Carrero, et al., “Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Known knowns and known unknowns,” Kidney International, vol. 105, no. 4, pp. 684–701, 2024, doi: 10.1016/j.kint.2023.10.016.
[15] C. M. Rhee, “The interaction between thyroid and kidney disease: An overview of the evidence,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 23, no. 5, pp. 407–415, 2016, doi: 10.1097/MED.0000000000000275.
